

JUNE 19-22

SAN DIEGO

CONVENTION.BIO.ORG • #BIO2017



The Global Event for Biotechnology


BIO 2017 BY THE NUMBERS

2017





74 48 COUNTRIES STATES



FEATURING SEVERAL THEMATIC EXHIBITS

- Innovation Zone
- Digital Health Zone
- Start-up Stadium
- BioProcess Zone
- BIO Talent Connect



MORE THAN 100 International and Domestic Public Officials



41,400
PARTNERING MEETINGS

16% GROWTH FROM 2016



50+ International, Regional and State Pavilions



+

60+ Patient Advocacy and Venture Philanthropy Organizations

145+
SESSIONS

18+
TRACKS

800+


Including **250** Company
Presentations





WHO ATTENDS BIO?

2017






From Every Channel of Biotech...

- Academic / University
- Business Development
- CM0 / CR0
- Consultant / Accounting / Financial
- Diagnostics & Devices
- Food & Agriculture
- Industrial & Environmental
- Manufacturing / Distribution / Operations
- Marketing / PR
- Non-Profilt
- Pharma
- Policy / Government Affairs / Advocacy
- Technology Transfer
- Therapeutics
- Venture Capital / Investor







ATTENDEE **STATS**, cont.

2017



74. COUNTRIES

48
STATES





MORE THAN 100 International and Domestic Public Officials



1/3
OF ATTENDEES ARE INTERNATIONAL

TOP 10 INTERNATIONAL DELEGATIONS



1 Canada



2 South Korea



3 United Kingdom



4 Japan



5 Germany



6 China



7 France



8 Australia



9 Brazil



10 Taiwan

TOP REASONS TO ATTEND BIO

2017



Network / PartnerWITH ATTENDEES AND EXHIBITORS



SEARCH FOR NEW

Innovations & Technology



Company Presentations / Exhibition

"**THE** place to meet everyone of importance in the industry."





BIO ONE-ON-ONE PARTNERINGTM

2017

PARTNERING TM
Powered by BIO

BIO One-on-One

Partnering™ provides

the opportunity

for biotechnology

and pharmaceutical

companies, academic research institutions and investors from around the world to schedule 30-minute face-to-face meetings to discuss potential partnerships. Meetings take place in the BIO Business Forum and the BIO Exhibition.

MORE THAN
41,400
PARTNERING
MEETINGS

16% GROWTH FROM 2016

35,000

PARTICIPATING ORGANIZATIONS





EDUCATION PROGRAM

2017



800+ SPEAKERS

Including 250 Company Presentations



145+ **SESSIONS**

TRACKS

SESSION TRACKS



Biofuels & Renewable Chemicals



Brain Health



Business Development & Finance



Critical Cross-Disciplinary Issues



Digital Health



Emerging Opportunities in Global Markets



Harnessing Big Data to Drive Innovation in Biomedicine



Intellectual **Property**



Infectious Diseases & Vaccines



Modern Aq Innovation



Next Generation Biotherapeutics



Oncology



Orphan & Rare Diseases



Personalized Medicine & Diagnostics



Regulatory Research



Translational Research



Value, Patient Access & Commercialization

26% ATTENDEDUCATION SESSIONS IN **BIO EXHIBITION**

Super Sessions

- So Many Choices: What's the Right Biomanufacturing Strategy for Me?
- Dealmakers' Intentions: 2017 Market Outlook
- Our Common Goal: Ensuring Access and Affordability of Innovative Medicines
- The Trade and Investment Policies of the Trump Administration
- The Scientific American WorldVIEW Super
 Session: Wrapping Up and Looking Forward

Fireside Chats

- Brent Saunders, Chairman, President and CEO,
 Allergan plc
- Lloyd Minor, MD, Dean, Stanford University School of Medicine
- **David Hung, MD**, *CEO*, Axovant Sciences
- Daniel Skovronsky, Senior Vice President, Clinical and Product Development at Eli Lilly and Company and Chairman, Avid Radiopharmaceuticals
- Francis deSouza, President & CEO, Illumina
- Kathleen Rubins, PhD, Astronaut, NASA
- Understanding the Patient Voice:
 Three Unique Perspectives on Healthcare



TOP 3

Attendee Sessions

The Trade and Investment Policies of the Trump Administration

- Innovations and Partnerships with the U.S. Department of Defense
- State of the Industry: Biotechnology
 Financing & Deal Making
 Findings from the Ernst & Young
 Biotechnology Annual Report

TOP 3

Attendee Tracks

Business Development & Finance



Oncology



Next Generation Biotherapeutics



DIVERSITY OF **EXPERTS**

2017



Martha BrumfieldPresident & CEO

Critical Path Institute



Margarita Chavez
Director, Ventures
& Early Stage
Collaborations
AbbVie



Dr. Sadhana Chitale, PhD, MBA *Director*New York University



Barbara Fiacco

Partner

Foley Hoag LLP



Dr. Carlo Incerti, MD Head Global Medical Affairs and Chair EuropaBio Sanofi Genzyme



Salvo La Rosa
Vice President Research
and Development
Children's Tumor
Foundation



Steve Lam
Senior Vice President,
Biologics
Patheon



Jeremy Levin, DPhil, MB *Chief Executive Officer*Ovid Therapeutics



Wen Luo, PhD *Chief Executive Officer*Denovo Biopharma



David Meeker, MD

Executive Vice President
and Head of Sanofi
Genzyme
Sanofi Genzyme



Lloyd Minor, MD
Dean, School
of Medicine
Stanford University



Katherine Needleman
Director of the Orphan
Products Grants
Program
US Food and Drug
Administration



Issi RozenChief Business Officer
Broad Institute of
Harvard and MIT



Rajeev Venkayya President, Vaccine Business Unit Takeda Vaccines



BIO KEYNOTES

2017



DAVID CAMERON

FORMER PRIME MINISTER OF THE UNITED KINGDOM, 2010-2016



ANN ROMNEY

FORMER FIRST LADY OF MASSACHUSETTS

PREVIOUS KEYNOTE SPEAKERS

2016

Will Smith

Dr. Benet Omalu

2015

Tom Brokaw

Eric Topol

Wynton Marsalis

2014

Hillary Clinton


Richard Branson



ACADEMIC CAMPUS

Visibility in the BIO Business Forum, access to partnering and exclusive networking

2017



13 ACADEMIC INSTITUTIONS REPRESENTED






















effective networking opportunity of my year."

"Nearly all my past and



THE UNIVERSITY
of NORTH CAROLINA
at CHAPEL HILL





As of May 16, 2017





REGISTRATION

convention@bio.org +1.202.962.6655

SPEAKING

program@bio.org +1.202.962.6655

EXHIBITING

exhibit@bio.org +1.202.312.9264

PARTNERING

biopartnering@bio.org +1.202.962.6666

SPONSORSHIPS & ADVERTISING

sponsor@bio.org +1.202.449.6381

All BIO is an excellent conference to network with businesses and individuals, learn about updates in all fields of biotechnology, and enjoy the hospitality and landscape of the venue city."

